Annual report pursuant to Section 13 and 15(d)

Segment Reporting - Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment (Detail)

v3.6.0.2
Segment Reporting - Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment (Detail) - USD ($)
 12 Months Ended
Nov. 30, 2016
Nov. 30, 2015
Segment Reporting Information [Line Items]    
Total net revenue $ 23,128,047 $ 21,091,431
Total cost of sales 5,774,800 5,630,865
Total operating profit 433,594 2,933,224
Total depreciation and amortization 154,673 92,110
Total interest expense 947,340 1,303,872
Total income tax benefit (expense) 1,159,412 7,156,822
Total other comprehensive income (135,524) 169,932
Total assets 19,538,468 19,497,946
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]    
Segment Reporting Information [Line Items]    
Total net revenue 22,777,919 20,620,138
Total cost of sales 5,446,126 5,276,125
Total operating profit 2,447,160 2,842,957
Total depreciation and amortization 240,916 218,568
Total interest expense 925,075 1,277,815
Total income tax benefit (expense) 1,141,823 7,166,789
Total other comprehensive income (135,524) 169,932
Total assets 18,960,261 16,697,621
PrepaCyte CB [Member]    
Segment Reporting Information [Line Items]    
Total net revenue 350,128 471,293
Total cost of sales 328,674 354,740
Total operating profit (2,013,566) 90,267
Total depreciation and amortization 45,735 22,640
Total interest expense 22,265 26,057
Total income tax benefit (expense) 17,589 (9,967)
Total assets $ 578,207 $ 2,800,325